Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Brain JNK and metabolic disease.

  • Nogueiras, Rubén
  • Sabio, Guadalupe
Obesity, which has long since reached epidemic proportions worldwide, is associated with long-term stress to a variety of organs and results in diseases including type 2 diabetes. In the brain, overnutrition induces hypothalamic stress associated with the activation of several signalling pathways, together with central insulin and leptin resistance. This central action of nutrient overload appears very rapidly, suggesting that nutrition-induced hypothalamic stress is a major upstream initiator of obesity and associated diseases. The cellular response to nutrient overload includes the activation of the stress-activated c-Jun N-terminal kinases (JNKs) JNK1, JNK2 and JNK3, which are widely expressed in the brain. Here, we review recent findings on the regulation and effects of these kinases, with particular focus on the hypothalamus, a key brain region in the control of energy and glucose homeostasis. JNK1 blocks the hypothalamic-pituitary-thyroid axis, reducing energy expenditure and promoting obesity. Recently, opposing roles have been identified for JNK1 and JNK3 in hypothalamic agouti gene-related protein (AgRP) neurons: while JNK1 activation in AgRP neurons induces feeding and weight gain and impairs insulin and leptin signalling, JNK3 (also known as MAPK10) deletion in the same neuronal population produces very similar effects. The opposing roles of these kinases, and the unknown role of hypothalamic JNK2, reflect the complexity of JNK biology. Future studies should address the specific function of each kinase, not only in different neuronal subsets, but also in non-neuronal cells in the central nervous system. Decoding the puzzle of brain stress kinases will help to define the central stimuli and mechanisms implicated in the control of energy balance. Graphical abstract.
Repisalud
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.

  • da Silva Lima, Natália
  • Fondevila, Marcos F
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, Maria
  • Gallet, Sarah
  • González-Rellan, Maria J
  • Fernandez, Uxia
  • Loyens, Anne
  • Garcia-Vence, Maria
  • Chantada-Vazquez, Maria Del Pilar
  • Bravo, Susana-Belén
  • Marañon, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C
  • Montero-Vallejo, Rocio
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Duran, Rocio
  • Romero-Gomez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martinez-Chantar, Maria L
  • Garcia-Monzon, Carmelo
  • Gonzalez-Rodriguez, Agueda
  • Aspichueta, Patricia
  • Nogueiras, Ruben
BACKGROUND & AIMS: Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown. METHODS: By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice. RESULTS: ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action. CONCLUSIONS: Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis. LAY SUMMARY: We show that autophagy-related gene 3 (ATG3) contributes to the progression of non-alcoholic fatty liver disease in humans and mice. Hepatic knockdown of ATG3 ameliorates the development of NAFLD by stimulating mitochondrial function. Thus, ATG3 is an important factor implicated in steatosis.